(E)-4-ethoxy-4'-methoxystilbene | 35135-40-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-4-ethoxy-4'-methoxystilbene
• 英文别名: 1-Ethoxy-4-[(1E)-2-(4-methoxyphenyl)ethenyl]benzene；1-ethoxy-4-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
• CAS: 35135-40-1
• 化学式: C₁₇H₁₈O₂
• 分子量: 254.329
• InChiKey: FHOAWKWHKPHWAG-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-碘苯甲醚 、 4-乙氧基苯乙烯 在 3-(anthracen-9-ylmethyl)-1-(3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)-1H-imidazol-3-ium chloride 、 palladium diacetate 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以84%的产率得到(E)-4-ethoxy-4'-methoxystilbene
  参考文献：
  名称：

  新型基于咔唑的N杂环卡宾配体可在Pd催化偶联过程中获得与合成相关的对苯二酚

  摘要：

  一系列新的咔唑基氮杂环卡宾（NHC）配体已通过简单且容易的合成路线进行合成，随后用于基于Pd /咔唑的NHC催化体系中，发现该化合物可有效催化Heck反应，以高收率提供取代的二苯乙烯衍生物。合成了几种具有生物活性的对苯二酚，包括萜烯，松油基乙烯基，三甲氧基白藜芦醇和白藜芦醇，而且三甲氧基白藜芦醇的放大倍数也达到了10 mmol。通过一锅法进行双串联化学选择性Heck反应，然后进行Miyaura硼化，可以扩展合成的应用范围，从而可以一步一步获得合成上有用的二苯乙烯基硼酸酯。相似地，

  DOI：

  10.1002/asia.201900419

文献信息

• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH
  申请人：Pierce William M.

  公开号：US20080221070A1

  公开（公告）日：2008-09-11

  Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R T ), having an affinity for bone; a Bone Active Portion (R A ) for interacting with and affecting bone; a Linking Portion (R L ) connecting the Bone Targeting Portion and the Bone Active Portion. The Bone Active Portion is derived from an estrogenic agent. Compounds can also include a Blocking Group (R P ) that reduces or eliminates the estrogenic activity of the Bone Active Portion.

  提供了针对骨骼的化合物和方法。这些化合物可以包括针对骨骼的部分（RT），具有与骨骼的亲和力；用于与骨骼相互作用并影响骨骼的活性部分（RA）；连接针对骨骼部分和活性部分的连接部分（RL）。活性部分来源于雌激素类药物。化合物还可以包括减少或消除活性部分雌激素活性的阻断基团（RP）。
• Substituted <i>trans</i>-Stilbenes, Including Analogues of the Natural Product Resveratrol, Inhibit the Human Tumor Necrosis Factor Alpha-Induced Activation of Transcription Factor Nuclear Factor KappaB
  作者：Justin J. Heynekamp、Waylon M. Weber、Lucy A. Hunsaker、Amanda M. Gonzales、Robert A. Orlando、Lorraine M. Deck、David L. Vander Jagt

  DOI：10.1021/jm060630x

  日期：2006.11.30

  The transcription factor nuclear factor kappaB (NF-kappa B), which regulates expression of numerous antiinflammatory genes as well as genes that promote development of the prosurvival, antiapoptotic state is up-regulated in many cancer cells. The natural product resveratrol, a polyphenolic trans-stilbene, has numerous biological activities and is a known inhibitor of activation of NF-kappa B, which may account for some of its biological activities. Resveratrol exhibits activity against a wide variety of cancer cells and has demonstrated activity as a cancer chemopreventive against all stages, i.e., initiation, promotion, and progression. The biological activities of resveratrol are often ascribed to its antioxidant activity. Both antioxidant activity and biological activities of analogues of resveratrol depend upon the number and location of the hydroxy groups. In the present study, phenolic analogues of resveratrol and a series of substituted trans-stilbenes without hydroxy groups were compared with resveratrol for their abilities to inhibit the human tumor necrosis factor alpha-induced (TNF-alpha) activation of NF-kappa B, using the Panomics NF-kappa B stable reporter cell line 293/NF-kappa B-luc. A series of 75 compounds was screened to identify substituted trans-stilbenes that were more active than resveratrol. Dose-response studies of the most active compounds were carried out to obtain IC50 values. Numerous compounds were identified that were more active than resveratrol, including compounds that were devoid of hydroxy groups and were 100-fold more potent than resveratrol. The substituted trans-stilbenes that were potent inhibitors of the activation of NF-kappa B generally did not exhibit antioxidant activity. The results from screening were confirmed using BV-2 microglial cells where resveratrol and analogues were shown to inhibit LPS-induced COX-2 expression.
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
• THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS
  申请人：STC. UNM

  公开号：US20160287531A1

  公开（公告）日：2016-10-06

  The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.